PBLS (Parabilis Medicines) 1-Year Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $38.85
! 2 Warning Signs
View Full Analysis

What is Parabilis Medicines 1-Year Share Buyback Ratio?

Parabilis Medicines PBLS -2.71% 10 1-Year Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,109 Biotechnology companies, Parabilis Medicines ranks worse than 90171.24% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Parabilis Medicines's current 1-Year Share Buyback Ratio was 0.00%.

PBLS's 1-Year Share Buyback Ratio is not ranked *
in the Biotechnology industry.
Industry Median: -14.2
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Parabilis Medicines  (NAS:PBLS) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Parabilis Medicines 1-Year Share Buyback Ratio Related Terms

PBLS vs DYN, ACAD, EWTX: 1-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Parabilis Medicines's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parabilis Medicines 1-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's 1-Year Share Buyback Ratio falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
1-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines 1-Year Share Buyback Ratio Calculation

Parabilis Medicines's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2024 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Dec. 2024 )
=(118.146 - 118.146) / 118.146
=0.0%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of 0.00 mean?
Parabilis Medicines (PBLS) has a 1-Year Share Buyback Ratio of 0.00 as of Dec. 2025. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #999999 out of 1109 companies in the Biotechnology industry.
Is Parabilis Medicines' 1-Year Share Buyback Ratio too high?
Parabilis Medicines' current 1-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Parabilis Medicines ranks #999999 out of 1109 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' 1-Year Share Buyback Ratio compare to DYN and ACAD?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #999999 out of 1109 companies for 1-Year Share Buyback Ratio. This places Parabilis Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Parabilis Medicines and its competitors. Parabilis Medicines's current 1-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current 1-Year Share Buyback Ratio of 0.00. The current 1-Year Share Buyback Ratio is 0.00. Parabilis Medicines' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current 1-Year Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.85
Price